Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 262

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 262
---
 is expanding the capabilities
of its current proprietary analytical software by adding Machine Learning and AI capabilities to it and training its classifier to optimize
its performance.

DiamiR began this initiative in
July 2023 through a service agreement with JADBio (jadbio.com), pursuant to which DiamiR purchased a nonexclusive, non-assignable, non-sublicensable,
license to use its Automated Machine Learning (AutoML) Platform and Services (the “JB License”) for development of predictive
models based on DiamiR microRNA panels and other factors for risk assessment in Alzheimer’s disease and Rett syndrome. Their AutoML
tools allows for supervised learning, developing methods falling in the class of feature selection (a.k.a., variable selection or attribute
selection), which in turn can be coupled with predictive modeling algorithms to identify (bio) signatures, defined as minimal-size subsets
of molecular and other biological measurements that collectively lead to optimal predictions. Initially DiamiR’s focus will be on
training and optimizing a miRNA panel and demographic risk factors, such as sex and age. Next, DiamiR will introduce protein biomarkers
to the classifier, re-training it to identify additional risk of progression information. There are no guarantees that DiamiR’s
AI/ML work will result in a working algorithm(s) or that the algorithms DiamiR develops will prove to be accurate. DiamiR relies on available
statistical approaches and their derivatives for our data analysis needs. The tools currently available to DiamiR do not guarantee a positive
outcome.

<div align='center'>135</div>

JADBio is a vendor, similar to other vendors with
which DiamiR can work; any data DiamiR generate belongs to DiamiR. DiamiR’s contract with JADBio expired in 2024 and DiamiR chose
not to renew it at this time.

Develop proprietary LDTs in DiamiR’s
CLIA-certified laboratory. DiamiR hs the capacity to process between about 3500 - 5500 tests per year. DiamiR plans on introducing automation
and robots into its lab operations to increase capacity, reduce turn-around-time (TAT), improve efficiency, drive lower COGS, and reduce
overhead expenses. DiamiR closely monitors FDA and congressional action around LDT statutes and will adjust its strategy accordingly.

Drive early adoption of the tests based on establishing collaborations
with leading academic centers and industrial partners to ensure strong support for the tests from